Hostname: page-component-54dcc4c588-hp6zs Total loading time: 0 Render date: 2025-10-09T18:37:58.038Z Has data issue: false hasContentIssue false

Changes in depression medication following the initial assessment by specialised psychiatry services in the Helsinki-Uusimaa Region

Published online by Cambridge University Press:  26 August 2025

J. Juntura*
Affiliation:
University of Helsinki
P. Näätänen
Affiliation:
Department of Psychiatry, Helsinki University Hospital, Helsinki
G. Joffe
Affiliation:
Department of Psychiatry, Helsinki University Hospital, Helsinki
J. Ekelund
Affiliation:
Department of Psychiatry, Helsinki University Hospital, Helsinki
R.-L. Leskelä
Affiliation:
Nordic Healthcare Group, Espoo, Finland
T. Ito
Affiliation:
Janssen EMEA, High Wycombe, United Kingdom
B. Rive
Affiliation:
Janssen EMEA, Paris, France
Y. Godinov
Affiliation:
Janssen EMEA, Sofia, Bulgaria
I. Eriksson
Affiliation:
Janssen EMEA, Solna, Sweden
P. Torkki
Affiliation:
University of Helsinki
*
*Corresponding author.

Abstract

Core share and HTML view are not available for this content. However, as you have access to this content, a full PDF is available via the ‘Save PDF’ action button.
Introduction

Depressive disorders often require specialised psychiatric services. Timely, appropriate medication initiation and/or change plays a crucial role in improving patient (pt) outcomes (Kraus et al. Transl Psychiatry 2019;9 127).

Objectives

Describe the type of, and time to, medication changes within 12 months of the initial assessment of pts with depression recorded by specialised psychiatric care (SPC).

Methods

This cohort study leveraged Finnish pt data from 19 registries from 2014–2020. Adult pts with a depression diagnosis recorded by SPC in the Helsinki and Uusimaa region in 2015 (with no depression diagnosis given by SPC within the previous year) were included. All treatments were recorded as monotherapy or combination/augmentation therapy. The Kaplan-Meier method was used to analyse time to treatment change (TTC).

Results

9305 pts were included; baseline characteristics are reported (Table 1). There was no change to the baseline treatment status in 39.7% of pts (Table 2). The most common change was from no medication to monotherapy (2138 pts [45.6% of those with no treatment before]). 2202 (23.7%) pts remained untreated throughout the study. Median (95% confidence interval) TTC following the initial assessment by SPC was 53 (50–56) days (Figure 1).

Image 1:

Image 2:

Image 3:

Conclusions

Around 40% of pts referred to SPC had no prior pharmacotherapy. Monotherapy was the most common treatment provided. Almost 40% of pts had no change in their baseline treatment over 12 months, highlighting the need for further research to optimise care.

Disclosure of Interest

None Declared

Information

Type
Abstract
Creative Commons
Creative Common License - CCCreative Common License - BY
This is an Open Access article, distributed under the terms of the Creative Commons Attribution licence (https://creativecommons.org/licenses/by/4.0/), which permits unrestricted re-use, distribution, and reproduction in any medium, provided the original work is properly cited.
Copyright
© The Author(s), 2025. Published by Cambridge University Press on behalf of European Psychiatric Association
Submit a response

Comments

No Comments have been published for this article.